AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8755854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent peritoneal dialysis
Number of subjects: 33
Study 8755854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 33
Study 8755854 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (HD and IPD)
Number of subjects: 33
Study 1655220 — intervention group
Group type: EXPERIMENTAL
Intervention: Edatrexate (10‐EdAM) 80 mg/m2, Cyclophosphamide 800 mg/m2, Cisplatin 80 mg/m2 on day 1, repeated every 3 weeks
Number of subjects: 32
Study 1655220 — intervention group
Group type: EXPERIMENTAL
Intervention: Edatrexate (10‐EdAM) 70 mg/m2, Cyclophosphamide 700 mg/m2, Cisplatin 70 mg/m2 on day 1, repeated every 3 weeks
Number of subjects: 32
Study 1655220 — intervention group
Group type: EXPERIMENTAL
Intervention: Major response
Number of subjects: 32
Study 1655220 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose schedule
Number of subjects: 32
Study 6304513 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 X 10(6) units intramuscularly before transplant, then three times a week for six weeks and twice a week for eight weeks, total of 102 X 10(6) units)
Number of subjects: 42
Study 6304513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given intramuscularly before transplant and following the same schedule as interferon)
Number of subjects: 42
Study 6304513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6304513 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 42
Study 6304513 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha and Placebo
Number of subjects: 42
Study 31401899 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (biosimilar to infliximab)
Number of subjects: 0
Study 31401899 — intervention group
Group type: COMPARATOR
Intervention: Infliximab RMP (reference medicinal product)
Number of subjects: 0
Study 27778642 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA)
Number of subjects: 0
Study 27778642 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 27778642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25730630 — intervention group
Group type: EXPERIMENTAL
Intervention: Temptation to drink (TTD)
Number of subjects: 1726
Study 25730630 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpose in life (PIL)
Number of subjects: 1726
Study 25730630 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal associations between TTD and PIL
Number of subjects: 1726
Study 23949057 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional-rTMS
Number of subjects: 12
Study 23949057 — intervention group
Group type: COMPARATOR
Intervention: Passive-rTMS
Number of subjects: 12
Study 21480966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 74
Study 21480966 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetic diet
Number of subjects: 74
Study 20025679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose i.v. iron therapy (LD-IVIT) - <or=50 mg/week of iron sucrose
Number of subjects: 119
Study 20025679 — intervention group
Group type: COMPARATOR
Intervention: Oral iron therapy (OIT)
Number of subjects: 119
Study 20025679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose i.v. iron therapy (LD-IVIT)
Number of subjects: 119
Study 16542286 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg infusion every 6 h
Number of subjects: 200
Study 16542286 — intervention group
Group type: COMPARATOR
Intervention: CIM 400 mg infusion every 12 h
Number of subjects: 200
Study 16542286 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg infusion every 12 h
Number of subjects: 200
Study 12767502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal triamcinolone acetonide (TCA) administration (6 administrations every third day)
Number of subjects: 36
Study 12767502 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued intrathecal TCA treatment (1 injection every 6 to 12 weeks)
Number of subjects: 36
Study 10930692 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-IPV//PRP-T
Number of subjects: 252
Study 10930692 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP//PRP-T+OPV
Number of subjects: 252
Study 10930692 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP+PRP-T+OPV
Number of subjects: 252
Study 9379341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus melatonin (20 mg/day orally in the evening)
Number of subjects: 70
Study 9379341 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin 20 mg/m2/day i.v. for 3 days and etoposide 100 mg/m2/day i.v. for 3 days)
Number of subjects: 70
Study 9379341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus melatonin
Number of subjects: 70
Study 9379341 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 70
Study 8268648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF) with constant dialysate Na (140 mEq/L)
Number of subjects: 10
Study 8268648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF) with varying dialysate Na (150 mEq/L in the first hour, 142 in the second, and 137 in the third)
Number of subjects: 10
Study 3890131 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine administration (2 g i.v. three times weekly for 6 weeks)
Number of subjects: 28
Study 3890131 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study 31409331 — intervention group
Group type: EXPERIMENTAL
Intervention: T33 (0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Number of subjects: 3
Study 31409331 — intervention group
Group type: EXPERIMENTAL
Intervention: T33 (2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Number of subjects: 3
Study 31409331 — intervention group
Group type: EXPERIMENTAL
Intervention: T33 (200 mg/kg and 600 mg/kg)
Number of subjects: 3
Study 29036711 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 2074
Study 29036711 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ECT)
Number of subjects: 2074
Study 27402551 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST administered via ACASI
Number of subjects: 502
Study 24709256 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily for 12 weeks with PegIFN/RBV
Number of subjects: 160
Study 24709256 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily for 24 weeks with PegIFN/RBV
Number of subjects: 160
Study 24709256 — intervention group
Group type: COMPARATOR
Intervention: Both groups (12-week and 24-week) received identical treatment from weeks 2 to 12
Number of subjects: 160
Study 24709256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 160
Study 24709256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 22200674 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA emulsion (docosahexaenoic acid)
Number of subjects: 0
Study 22200674 — intervention group
Group type: EXPERIMENTAL
Intervention: OA emulsion (oleic acid)
Number of subjects: 0
Study 22200674 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 0
Study 20409497 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based counseling (n=401)
Number of subjects: 1202
Study 20409497 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone-based counseling (PTC; n=402)
Number of subjects: 1202
Study 20409497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PTC and web counseling (n=399)
Number of subjects: 1202
Study 17913317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5mg/kg
Number of subjects: 120
Study 17913317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5mg/kg plus dexamethasone 8 mg
Number of subjects: 120
Study 17913317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15914508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (0.8 g/kg; LP)
Number of subjects: 5
Study 15914508 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein diet (1.8 g/kg; MP)
Number of subjects: 5
Study 15914508 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (3.6 g/kg; HP)
Number of subjects: 5
Study 11718736 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-Fixator
Number of subjects: 1229
Study 10229559 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost i.v. infusion up to 2 ng/Kg/min for 6/h/day for 28 days (Group A)
Number of subjects: 20
Study 10229559 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost i.v. infusion up to 1.5 ng/Kg/min for 16/h/day for 7 days (Group B)
Number of subjects: 20
Study 7913730 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of zidovudine daily
Number of subjects: 1565
Study 7913730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1565
Study 7913730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of zidovudine daily
Number of subjects: 1565
Study 2493733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (2 mg/kg/10 minutes)
Number of subjects: 40
Study 2493733 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (10 mg/1 minute)
Number of subjects: 40
Study 31651843 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (YT)
Number of subjects: 160
Study 31651843 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 160
Study 28692485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5-3 mg/day
Number of subjects: 4
Study 28692485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 4.5-6 mg/day
Number of subjects: 4
Study 28692485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 9-12 mg/day
Number of subjects: 4
Study 28692485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 25289715 — intervention group
Group type: COMPARATOR
Intervention: Creatine (Cr; 5 g creatine plus 5 g maltodextrose)
Number of subjects: 44
Study 25289715 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine plus creatine (β‐ALA+Cr; 1.6 g beta alanine plus 5 g creatine plus 3.4 g maltodextrose)
Number of subjects: 44
Study 25289715 — intervention group
Group type: COMPARATOR
Intervention: Beta-alanine (β‐ALA; 1.6 g beta alanine plus 8.4 g maltodextrose)
Number of subjects: 44
Study 25289715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P; 10 g maltodextrose)
Number of subjects: 44
Study 24239154 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term humanistic-existential psychotherapy (STP)
Number of subjects: 101
Study 24239154 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiological therapy only
Number of subjects: 101
Study 21508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 170
Study 21508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 170
Study 21508145 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine plus selenomethionine
Number of subjects: 170
Study 21508145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 18827035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette packs with progressively fewer branding design elements
Number of subjects: 813
Study 18827035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardboard brown packs with minimal branding
Number of subjects: 813
Study 18827035 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packs
Number of subjects: 813
Study 18827035 — intervention group
Group type: COMPARATOR
Intervention: Original branded packs
Number of subjects: 813
Study 16014759 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 18
Study 16014759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 18
Study 16014759 — intervention group
Group type: COMPARATOR
Intervention: None (non-supplemented)
Number of subjects: 18
Study 12838090 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Number of subjects: 91
Study 12838090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham manipulation
Number of subjects: 91
Study 12838090 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 91
Study 11129744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks
Number of subjects: 53
Study 11129744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9053827 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-enriched group (1200 mg RDA)
Number of subjects: 22
Study 9053827 — intervention group
Group type: COMPARATOR
Intervention: Control group (728 mg calcium)
Number of subjects: 22
Study 1645047 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug A (original piroxicam)
Number of subjects: 14
Study 1645047 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug B (generic piroxicam)
Number of subjects: 14
Study 1645047 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug C (another generic piroxicam)
Number of subjects: 14
Study 1645047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis
Number of subjects: 14
Study 1645047 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease treatment
Number of subjects: 14
Study 6389520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 84
Study 6389520 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 84
Study 29705152 — intervention group
Group type: EXPERIMENTAL
Intervention: 18FDG PET/CT
Number of subjects: 72
Study 29705152 — intervention group
Group type: COMPARATOR
Intervention: 64MDCT
Number of subjects: 72
Study 27323902 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles carboplatin-olaparib followed by olaparib monotherapy 300 mg BID
Number of subjects: 110
Study 27323902 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m2 BID day 1-14 q day 22
Number of subjects: 110
Study 23870160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose methylprednisolone (30 mg/kg per dose, given 8 hours preoperatively and operatively)
Number of subjects: 68
Study 23870160 — intervention group
Group type: COMPARATOR
Intervention: Single-dose methylprednisolone (30 mg/kg per dose, given operatively)
Number of subjects: 68
Study 23870160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (2-dose and single-dose)
Number of subjects: 68
Study 23870160 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative response
Number of subjects: 68
Study 23870160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose methylprednisolone
Number of subjects: 68
Study 23870160 — intervention group
Group type: COMPARATOR
Intervention: Single-dose methylprednisolone
Number of subjects: 68
Study 23446065 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CBT + milnacipran 100 mg/d)
Number of subjects: 58
Study 23446065 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran + education
Number of subjects: 58
Study 23446065 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 58
Study 21097770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 207
Study 21097770 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-supplemented diets
Number of subjects: 207
Study 21097770 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral glutamine
Number of subjects: 207
Study 21097770 — intervention group
Group type: EXPERIMENTAL
Intervention: General RCTs
Number of subjects: 207
Study 18426835 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum parathyroid hormone (PTH) levels (> or =63 ng/l, IV quartile cut point)
Number of subjects: 567
Study 18426835 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum parathyroid hormone (PTH) levels after controlling for age, gender, co-morbidity, and creatinine
Number of subjects: 567
Study 18426835 — intervention group
Group type: COMPARATOR
Intervention: Serum calcium (Ca(2+)) levels
Number of subjects: 567
Study 15995109 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 1223
Study 12926103 — intervention group
Group type: EXPERIMENTAL
Intervention: YM511 0.3 mg/day
Number of subjects: 98
Study 12926103 — intervention group
Group type: EXPERIMENTAL
Intervention: YM511 (all doses)
Number of subjects: 98
Study 10591935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine motion analysis using three-dimensional electrogoniometry
Number of subjects: 289
Study 9103689 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seropositive mothers
Number of subjects: 265
Study 9103689 — intervention group
Group type: COMPARATOR
Intervention: HIV seronegative mothers
Number of subjects: 265
Study 1909052 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 138
Study 1909052 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 138
Study 6643335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone 2 g intravenous infusion over 15 min
Number of subjects: 10
Study 3970361 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the periaqueductal gray region (n = 16)
Number of subjects: 33
Study 3970361 — intervention group
Group type: COMPARATOR
Intervention: No electrical stimulation (Control group, n = 17)
Number of subjects: 33
Study 29038234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneous every 4 weeks for 16 weeks (DB)
Number of subjects: 115
Study 29038234 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 16 weeks (DB)
Number of subjects: 115
Study 29038234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide during DB and IOL treatment
Number of subjects: 115
Study 29038234 — intervention group
Group type: COMPARATOR
Intervention: Placebo during DB and IOL treatment
Number of subjects: 115
Study 27371758 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐BiPAP
Number of subjects: 540
Study 27371758 — intervention group
Group type: COMPARATOR
Intervention: n‐CPAP
Number of subjects: 540
Study 24142804 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (Coruno® 16 mg, once daily)
Number of subjects: 50
Study 24142804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22865782 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) treatment
Number of subjects: 1485
Study 19793779 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond‐LR
Number of subjects: 40
Study 19793779 — intervention group
Group type: COMPARATOR
Intervention: Fuji Ortho‐LC
Number of subjects: 40
Study 18487894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (3-month, 36 sessions)
Number of subjects: 14
Study 18487894 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 14
Study 15680143 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertions of permission
Number of subjects: 0
Study 15680143 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertions of prohibitions
Number of subjects: 0
Study 12573372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic arterial (IHA) chemotherapy (folinic acid 200 mg/m2, fluorouracil 400 mg/m2 over 15 mins and 22‐h infusion 1600 mg/m2, day 1 and 2, repeated every 14 days)
Number of subjects: 290
Study 12573372 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (folinic acid 200 mg/m2, fluorouracil bolus 400 mg/m2 and 22‐h infusion 600 mg/m2, day 1 and 2, repeated every 14 days)
Number of subjects: 290
Study 12573372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IHA and intravenous)
Number of subjects: 290
Study 10386280 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 150
Study 10386280 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms/kg
Number of subjects: 150
Study 10386280 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg plus Droperidol 20 micrograms/kg
Number of subjects: 150
Study 10386280 — intervention group
Group type: COMPARATOR
Intervention: Granisetron‐Droperidol combination
Number of subjects: 150
Study 8681664 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 1004
Study 8681664 — intervention group
Group type: COMPARATOR
Intervention: pMDI
Number of subjects: 1004
Study 1920171 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of heart failure
Number of subjects: 0
Study 6314107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 37
Study 6314107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29947060 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla300)
Number of subjects: 30
Study 29947060 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec (Deg)
Number of subjects: 30
Study 26902064 — intervention group
Group type: EXPERIMENTAL
Intervention: Video demonstration
Number of subjects: 80
Study 26902064 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 80
Study 23141150 — intervention group
Group type: EXPERIMENTAL
Intervention: M9L10 (melphalan 9 mg/m²/d and lenalidomide 10 mg/d)
Number of subjects: 56
Study 23141150 — intervention group
Group type: EXPERIMENTAL
Intervention: M6L10 (melphalan 6 mg/m²/d and lenalidomide 10 mg/d)
Number of subjects: 56
Study 23141150 — intervention group
Group type: EXPERIMENTAL
Intervention: M4L15 (melphalan 4 mg/m²/d and lenalidomide 15 mg/d)
Number of subjects: 56
Study 23141150 — intervention group
Group type: EXPERIMENTAL
Intervention: M5L10 (melphalan 5 mg/m²/d and lenalidomide 10 mg/d)
Number of subjects: 56
Study 21600053 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentorship program for 2 months
Number of subjects: 0
Study 21600053 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 0
Study 20128336 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST; n = 12)
Number of subjects: 24